Johnson & Johnson embarks on supply chain restructuring
The project, which is largely tied to the innovative medicine segment, will see the company exit certain facilities and incur costs of up to $750 million.
Source Lens
Industry Context
Useful background context, but lower-priority than direct platform, community, or operator intelligence.
Impact Level
medium
Use this briefing to decide whether your team needs an immediate workflow, policy, or reporting change.
Key Stat / Trigger
No single quantitative trigger surfaced in this report.
Focus on the operational implication, not just the headline.
Full Coverage
An article from Johnson & Johnson embarks on supply chain restructuring The project, which is largely tied to the innovative medicine segment, will see the company exit certain facilities and incur costs of up to $750 million.
Published July 31, 2026 Phil Neuffer Lead Editor Share Copy link Email / Print License Add us on Google A car drives along a road next to a sign for at the Johnson & Johnson campus in Jacksonville, Florida, on April 10, 2026. The company said its supply chain restructuring effort launched in fiscal Q2 2026 will be completed by the end of fiscal 2029.
Jeff Schear via Getty Images Listen to the article 1 min This audio is auto-generated. Please let us know if you have feedback. Johnson & Johnson is undergoing a restructuring of its supply chain, primarily in its innovative medicine segment, according to a July 15 earnings release.
Begun in fiscal Q2 2026, the initiative involves the exit of certain manufacturing locations as the company attempts to streamline operations, per the release. Johnson & Johnson did not immediately respond to a request for additional information about which facilities it planned to exit.
Johnson & Johnson expects to complete the project by the end of fiscal year 2029, with related costs estimated to reach up to $750 million driven by charges tied to site and supplier exits, decommissioning and asset impairments.
The company already incurred $200 million in restructuring expenses for the effort in fiscal Q2, mostly related to asset impairments. As Johnson & Johnson rearranges its innovative medicine supply chain, it has been making major investments in domestic production elsewhere across the business.
Last month, the medical product manufacturer said it would spend $1 billion to construct a contact lens manufacturing plant in Jacksonville, Florida, over the next two years. The company also laid out a plan to invest $55 billion in U. S. production in January, including a cell therapy manufacturing site in Pennsylvania and a drug facility in North Carolina.
Recommended Reading Drugmaker AbbVie chooses North Carolina for $1. 4B manufacturing campus Manufacturing Dive Eli Lilly plans $3. 5B weight-loss drug factory By Nathan Owens • Feb. 5, 2026 Add us on Google Share Copy link Email / Print License Filed Under: Operations Management, Manufacturing
Original Source
This briefing is based on reporting from Supply Chain Dive. Use the original post for full primary-source context.
Style
Audience